Mohammad Qutub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Qutub has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Amol Tatode
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Rashtrasant Tukdoji Maharaj Nagpur University, Nagpur, Maharashtra, India
21 shared publications - Tanvi Premchandani
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Rashtrasant Tukdoji Maharaj Nagpur University, Nagpur, Maharashtra, India
14 shared publications - Ujban Md Hussain
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, India
12 shared publications - Milind Umekar
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, India
10 shared publications Jayshree Taksande
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India
8 shared publicationsTanvi Premchandani
8 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 7 (3) , 506-515
Nanotechnology-driven delivery of Cordycepin derived from Cordyceps species: Mainly focusing on application of inflammatory pulmonary disease and lung cancer
- 1 September 2026
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 7 (3) , 506-515
Open AccessNanotechnology-driven delivery of Cordycepin derived from Cordyceps species: Mainly focusing on application of inflammatory pulmonary disease and lung cancer
- 28 June 2026
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 356, 103984
Hybrid clay-biopolymer nanocomposites as multifunctional materials for biomedical and environmental applications
- 28 June 2026
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 356, 103984
Hybrid clay-biopolymer nanocomposites as multifunctional materials for biomedical and environmental applications
- 7 April 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (6) , 111728
CAR-NK cell therapy for overcoming antigen heterogeneity and immunosuppressive tumor microenvironments
- 7 April 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (6) , 111728
CAR-NK cell therapy for overcoming antigen heterogeneity and immunosuppressive tumor microenvironments
- 19 February 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 400
Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges
Glioblastoma (GBM) leverages exosomes to drive tumor progression, immunosuppression, and therapy resistance through transfer of oncogenic miRNAs, circRNAs, and proteins. These vesicles reprogram the tumor microenvironment (TME) by activating pathways such as TREM1 in microglia and STAT3-mediated vasculogenic mimicry. Exosomal nucleic acids, including circZNF800 and miR-374b-3p, serve as non-invasive biomarkers for recurrence and treatment monitoring. Advances in engineering, such as Angiopep-2-functionalized exosomes for blood-brain barrier penetration and CRISPR-Cas9-loaded vesicles targeting resistance genes, highlight their therapeutic potential. Challenges in heterogeneity, standardization, and scalable production underscore the need for interdisciplinary innovation to translate exosome-based strategies into clinical practice.
- 19 February 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 400
Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges
Glioblastoma (GBM) leverages exosomes to drive tumor progression, immunosuppression, and therapy resistance through transfer of oncogenic miRNAs, circRNAs, and proteins. These vesicles reprogram the tumor microenvironment (TME) by activating pathways such as TREM1 in microglia and STAT3-mediated vasculogenic mimicry. Exosomal nucleic acids, including circZNF800 and miR-374b-3p, serve as non-invasive biomarkers for recurrence and treatment monitoring. Advances in engineering, such as Angiopep-2-functionalized exosomes for blood-brain barrier penetration and CRISPR-Cas9-loaded vesicles targeting resistance genes, highlight their therapeutic potential. Challenges in heterogeneity, standardization, and scalable production underscore the need for interdisciplinary innovation to translate exosome-based strategies into clinical practice.
- Open Access
- 10 February 2026
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 5 (1) , 15
Correction: Premchandani et al. Engineered Exosomes as Smart Drug Carriers: Overcoming Biological Barriers in CNS and Cancer Therapy. Drugs Drug Candidates 2025, 4, 19
- 10 February 2026
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 5 (1) , 15
Open AccessCorrection: Premchandani et al. Engineered Exosomes as Smart Drug Carriers: Overcoming Biological Barriers in CNS and Cancer Therapy. Drugs Drug Candidates 2025, 4, 19
- 8 January 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 220, 114983
Injectable poloxamer-based thermogel as a delivery platform for agmatine and hyaluronic acid in muscle tissue engineering
- 8 January 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 220, 114983
Injectable poloxamer-based thermogel as a delivery platform for agmatine and hyaluronic acid in muscle tissue engineering
- 27 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 73
Development of a Gellan–Carbopol in Situ Gel System for Intranasal Delivery of Artemether-Loaded SLNs: Optimization and Kinetic Evaluation
- 27 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 73
Development of a Gellan–Carbopol in Situ Gel System for Intranasal Delivery of Artemether-Loaded SLNs: Optimization and Kinetic Evaluation
- 10 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 182
Rap1-Dependent pathways in depression: Genetic, Epigenetic, and neuroinflammatory mechanisms shaping synaptic resilience
Rap1, a small GTPase integral to synaptic plasticity, has emerged as a pivotal regulator in the pathophysiology of depression, bridging molecular, genetic, and environmental mechanisms. This review synthesizes evidence highlighting Rap1's role in long-term depression (LTD) and dendritic spine remodeling, where isoform-specific interactions (Rap1 vs. Rap2) modulate AMPA receptor trafficking and synaptic resilience. Genetic studies implicate Rap1-associated pathways, such as DOCK2 and DIRAS2, in postpartum depression, while postmortem analyses reveal reduced Rap1 activity in mood-related brain regions of depressed individuals. Epigenetic regulation, particularly stress-induced FTO downregulation, disrupts Rap1-dependent synaptic protein translation, linking environmental stressors to maladaptive plasticity. Neuroimmune crosstalk further underscores Rap1's dual role in synaptic and inflammatory signaling, as seen in comorbid depression and atopic dermatitis. Environmental toxins like cadmium dysregulate Rap1 via oxidative stress and epigenetic modifications, while phytocannabinoids modulate Rap1-ERK pathways to enhance neuroprotection. Therapeutic strategies, including vortioxetine and natural compounds like Modified Xiaoyaosan, target Rap1 to restore synaptic homeostasis. Emerging pathways, such as circadian disruptions and gut-brain axis interactions, suggest novel mechanisms by which Rap1 integrates systemic and neuronal stress responses. Unresolved questions persist regarding Rap1 isoform specificity, spatiotemporal regulation, and glial-neuronal metabolic coupling, necessitating advanced tools like biosensors and organoid models to unravel its pleiotropic roles in depression.
- 10 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 182
Rap1-Dependent pathways in depression: Genetic, Epigenetic, and neuroinflammatory mechanisms shaping synaptic resilience
Rap1, a small GTPase integral to synaptic plasticity, has emerged as a pivotal regulator in the pathophysiology of depression, bridging molecular, genetic, and environmental mechanisms. This review synthesizes evidence highlighting Rap1's role in long-term depression (LTD) and dendritic spine remodeling, where isoform-specific interactions (Rap1 vs. Rap2) modulate AMPA receptor trafficking and synaptic resilience. Genetic studies implicate Rap1-associated pathways, such as DOCK2 and DIRAS2, in postpartum depression, while postmortem analyses reveal reduced Rap1 activity in mood-related brain regions of depressed individuals. Epigenetic regulation, particularly stress-induced FTO downregulation, disrupts Rap1-dependent synaptic protein translation, linking environmental stressors to maladaptive plasticity. Neuroimmune crosstalk further underscores Rap1's dual role in synaptic and inflammatory signaling, as seen in comorbid depression and atopic dermatitis. Environmental toxins like cadmium dysregulate Rap1 via oxidative stress and epigenetic modifications, while phytocannabinoids modulate Rap1-ERK pathways to enhance neuroprotection. Therapeutic strategies, including vortioxetine and natural compounds like Modified Xiaoyaosan, target Rap1 to restore synaptic homeostasis. Emerging pathways, such as circadian disruptions and gut-brain axis interactions, suggest novel mechanisms by which Rap1 integrates systemic and neuronal stress responses. Unresolved questions persist regarding Rap1 isoform specificity, spatiotemporal regulation, and glial-neuronal metabolic coupling, necessitating advanced tools like biosensors and organoid models to unravel its pleiotropic roles in depression.